Search NLS News

For the past 14 years Jutta Heix has been an important cog in the wheel in accelerating the development of new cancer treatments and diagnostics – connecting and helping innovators and putting Norwegian oncology on the global map.

Valo Therapeutics has announced the exclusive licensing of intellectual property rights (IPR) from the University of Helsinki for the institution’s innovative PeptiCHIP technology. Following further validation by ValoTx, and the achievement of specific milestones, the IPR will transfer in full to the company. This is a strategically important addition for the company as it will […]

AstraZeneca’s Tezspire (tezepelumab) has been recommended for marketing authorisation in the European Union (EU) as an add-on therapy in patients 12 years and older with severe asthma who are inadequately controlled with high dose inhaled corticosteroids plus another medicinal product for maintenance treatment. The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency […]

Calliditas Therapeutics has added two members to its management team, Head of Human Resources Sandra Frithiof and Group General Counsel Jonathan Schur. Jonathan Schur has over 40 years of experience as a lawyer, is a member of the New York Bar, and is a former member of the Paris Bar. In private practice he worked […]

Valo Therapeutics has announced four appointments to its Scientific Advisory Board (SAB), Professor Paolo A. Ascierto, Dr Jeffery Bockman, Professor Malcolm K. Brenner, and Professor Kevin Harrington. “We are delighted to welcome our distinguished, and expert, new SAB members. They bring a wealth of scientific and clinical understanding which will be of great help in […]

The FDA has granted 510(k) clearance for the product DiviTumTKa as an aid in monitoring disease progression in previously diagnosed hormone receptor positive, metastatic postmenopausal female breast cancer patients. “We are excited to have received the formal approval from FDA for our DiviTumTKa assay, which is the first FDA cleared biomarker in this field. This […]

Iconovo has received a grant of USD 883,800 from the Bill & Melinda Gates Foundation. The grant work plan is focused on the development of a low-cost device that can provide delivery of medical compounds to the full (upper and lower) respiratory tract and will be performed in the period August 2022 – June 2023. […]

The European Commission (EC) has extended the marketing authorization for the company’s smallpox vaccine, IMVANEX to include protection from monkeypox and disease caused by vaccinia virus. The approval, which follows a positive opinion by the Committee for Medicinal Products for Human Use (CHMP) on July 22, 2022, is valid in all European Union Member States […]

The company has announced the appointment of Klaus Edvardsen as Chief Development Officer. “I am very pleased to welcome Klaus to Nykode Therapeutics’ executive management team. Klaus brings tremendous international leadership experience in directing successful drug development programs at renowned biopharmaceutical companies. As Nykode’s candidates continue to advance through the clinical, we are eager for […]

Mendus has announced the publication of in vivo data demonstrating significant anti-tumor synergies between the company’s allogeneic dendritic cell-based immune primer program ilixadencel and immune checkpoint inhibition via CTLA-4 blockade in the peer-reviewed journal OncoImmunology. “These preclinical data underpin the rationale behind our immune primer in playing multiple roles in overcoming immunosuppression and rewiring the […]